ATE320498T1 - Übersekretierte peptide, deren herstellung, und gleichzeitige verbesserung der sekretierten form eines oder mehrerer anderer polypeptide - Google Patents
Übersekretierte peptide, deren herstellung, und gleichzeitige verbesserung der sekretierten form eines oder mehrerer anderer polypeptideInfo
- Publication number
- ATE320498T1 ATE320498T1 AT02716745T AT02716745T ATE320498T1 AT E320498 T1 ATE320498 T1 AT E320498T1 AT 02716745 T AT02716745 T AT 02716745T AT 02716745 T AT02716745 T AT 02716745T AT E320498 T1 ATE320498 T1 AT E320498T1
- Authority
- AT
- Austria
- Prior art keywords
- protein
- dna sequence
- codon
- lys
- arg
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 6
- 102000004196 processed proteins & peptides Human genes 0.000 title 2
- 229920001184 polypeptide Polymers 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 abstract 6
- 102000004169 proteins and genes Human genes 0.000 abstract 6
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 5
- 108020004705 Codon Proteins 0.000 abstract 4
- 150000001413 amino acids Chemical group 0.000 abstract 4
- 239000000126 substance Chemical group 0.000 abstract 3
- 230000032258 transport Effects 0.000 abstract 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 abstract 2
- 102000005367 Carboxypeptidases Human genes 0.000 abstract 1
- 108010006303 Carboxypeptidases Proteins 0.000 abstract 1
- 108020004414 DNA Proteins 0.000 abstract 1
- 108010016626 Dipeptides Proteins 0.000 abstract 1
- 101710188306 Protein Y Proteins 0.000 abstract 1
- 230000004071 biological effect Effects 0.000 abstract 1
- 230000015556 catabolic process Effects 0.000 abstract 1
- 238000006731 degradation reaction Methods 0.000 abstract 1
- 230000001771 impaired effect Effects 0.000 abstract 1
- 239000012528 membrane Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000028327 secretion Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/815—Protease inhibitors from leeches, e.g. hirudin, eglin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- Plant Pathology (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10108100A DE10108100A1 (de) | 2001-02-20 | 2001-02-20 | Verwendung supersekretierbarer Peptide in Verfahren zu deren Herstellung und paralleler Verbesserung der Exportate eines oder mehrerer anderer Polypeptide von Interesse |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE320498T1 true ATE320498T1 (de) | 2006-04-15 |
Family
ID=7674831
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02716745T ATE320498T1 (de) | 2001-02-20 | 2002-02-08 | Übersekretierte peptide, deren herstellung, und gleichzeitige verbesserung der sekretierten form eines oder mehrerer anderer polypeptide |
Country Status (20)
| Country | Link |
|---|---|
| EP (1) | EP1364030B1 (de) |
| JP (1) | JP4243103B2 (de) |
| KR (1) | KR100858008B1 (de) |
| CN (1) | CN100575493C (de) |
| AT (1) | ATE320498T1 (de) |
| AU (1) | AU2002247696B2 (de) |
| BR (1) | BR0207385A (de) |
| CA (1) | CA2438935C (de) |
| CY (1) | CY1105696T1 (de) |
| DE (2) | DE10108100A1 (de) |
| DK (1) | DK1364030T3 (de) |
| ES (1) | ES2258619T3 (de) |
| IL (1) | IL157415A0 (de) |
| MX (1) | MXPA03007115A (de) |
| NO (1) | NO331375B1 (de) |
| NZ (1) | NZ527641A (de) |
| PE (1) | PE20020875A1 (de) |
| PT (1) | PT1364030E (de) |
| WO (1) | WO2002066628A2 (de) |
| ZA (1) | ZA200305867B (de) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2004226162A1 (en) * | 2003-04-04 | 2004-10-14 | Universite De Lausanne | Peptabody for cancer treatment |
| DE102006031962A1 (de) | 2006-07-11 | 2008-01-17 | Sanofi-Aventis Deutschland Gmbh | Amidiertes Insulin Glargin |
| DE102006031955A1 (de) | 2006-07-11 | 2008-01-17 | Sanofi-Aventis Deutschland Gmbh | Verfahren zur Herstellung von Insulinanaloga mit dibasischem B-Kettenende |
| PT3228320T (pt) | 2008-10-17 | 2020-03-26 | Sanofi Aventis Deutschland | Combinação de uma insulina e de um agonista do glp-1 |
| KR101853606B1 (ko) | 2009-07-06 | 2018-05-03 | 사노피-아벤티스 도이칠란트 게엠베하 | 메티오닌을 함유하는 수성 인슐린 제제 |
| KR101337322B1 (ko) | 2009-11-13 | 2013-12-06 | 사노피-아벤티스 도이칠란트 게엠베하 | Ｇｌｐ-1 효능제 및 메티오닌을 포함하는 약제학적 조성물 |
| DK2498802T3 (en) | 2009-11-13 | 2015-04-13 | Sanofi Aventis Deutschland | Pharmaceutical composition comprising a GLP-1 agonist, insulin and a methionine |
| ES2606554T3 (es) | 2010-08-30 | 2017-03-24 | Sanofi-Aventis Deutschland Gmbh | Uso de AVE0010 para la fabricación de un medicamento para el tratamiento de la diabetes mellitus de tipo 2 |
| US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
| PL2750699T3 (pl) | 2011-08-29 | 2015-12-31 | Sanofi Aventis Deutschland | Kombinacja farmaceutyczna do stosowania w kontroli glikemii u pacjentów z cukrzycą typu 2 |
| AR087744A1 (es) | 2011-09-01 | 2014-04-16 | Sanofi Aventis Deutschland | Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa |
| AU2015359376B2 (en) | 2014-12-12 | 2021-09-09 | Sanofi-Aventis Deutschland Gmbh | Insulin glargine/lixisenatide fixed ratio formulation |
| TWI748945B (zh) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患治療 |
| TW201705975A (zh) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患之治療 |
| CN108866205A (zh) * | 2018-07-25 | 2018-11-23 | 中国食品药品检定研究院 | 基于分子生物学方法鉴别菲牛蛭的特异性引物 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE58906966D1 (de) * | 1988-06-23 | 1994-03-24 | Hoechst Ag | Mini-Proinsulin, seine Herstellung und Verwendung. |
| GB8927722D0 (en) * | 1989-12-07 | 1990-02-07 | British Bio Technology | Proteins and nucleic acids |
| FI92601C (fi) * | 1992-03-11 | 1994-12-12 | Marja Makarow | Menetelmä hyötyproteiinien erittämiseksi hiivoista |
-
2001
- 2001-02-20 DE DE10108100A patent/DE10108100A1/de not_active Withdrawn
-
2002
- 2002-02-06 PE PE2002000083A patent/PE20020875A1/es not_active Application Discontinuation
- 2002-02-08 BR BR0207385-4A patent/BR0207385A/pt not_active IP Right Cessation
- 2002-02-08 WO PCT/EP2002/001306 patent/WO2002066628A2/en not_active Ceased
- 2002-02-08 DE DE60209883T patent/DE60209883T2/de not_active Expired - Lifetime
- 2002-02-08 KR KR1020037010738A patent/KR100858008B1/ko not_active Expired - Fee Related
- 2002-02-08 AT AT02716745T patent/ATE320498T1/de active
- 2002-02-08 EP EP02716745A patent/EP1364030B1/de not_active Expired - Lifetime
- 2002-02-08 ES ES02716745T patent/ES2258619T3/es not_active Expired - Lifetime
- 2002-02-08 JP JP2002566335A patent/JP4243103B2/ja not_active Expired - Fee Related
- 2002-02-08 CN CN02806848A patent/CN100575493C/zh not_active Expired - Fee Related
- 2002-02-08 AU AU2002247696A patent/AU2002247696B2/en not_active Ceased
- 2002-02-08 IL IL15741502A patent/IL157415A0/xx not_active IP Right Cessation
- 2002-02-08 PT PT02716745T patent/PT1364030E/pt unknown
- 2002-02-08 MX MXPA03007115A patent/MXPA03007115A/es active IP Right Grant
- 2002-02-08 NZ NZ527641A patent/NZ527641A/en not_active IP Right Cessation
- 2002-02-08 CA CA2438935A patent/CA2438935C/en not_active Expired - Fee Related
- 2002-02-08 DK DK02716745T patent/DK1364030T3/da active
-
2003
- 2003-07-30 ZA ZA200305867A patent/ZA200305867B/en unknown
- 2003-08-19 NO NO20033671A patent/NO331375B1/no not_active IP Right Cessation
-
2006
- 2006-06-07 CY CY20061100751T patent/CY1105696T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN1527882A (zh) | 2004-09-08 |
| CN100575493C (zh) | 2009-12-30 |
| NO20033671L (no) | 2003-10-17 |
| WO2002066628A2 (en) | 2002-08-29 |
| KR20030074832A (ko) | 2003-09-19 |
| MXPA03007115A (es) | 2003-11-18 |
| EP1364030B1 (de) | 2006-03-15 |
| DE10108100A1 (de) | 2002-08-29 |
| ES2258619T3 (es) | 2006-09-01 |
| IL157415A0 (en) | 2004-03-28 |
| BR0207385A (pt) | 2004-02-10 |
| CA2438935C (en) | 2012-01-24 |
| WO2002066628A3 (en) | 2002-11-14 |
| ZA200305867B (en) | 2004-06-29 |
| KR100858008B1 (ko) | 2008-09-11 |
| NO20033671D0 (no) | 2003-08-19 |
| DK1364030T3 (da) | 2006-07-17 |
| PE20020875A1 (es) | 2002-10-31 |
| JP4243103B2 (ja) | 2009-03-25 |
| CA2438935A1 (en) | 2002-08-29 |
| NZ527641A (en) | 2005-03-24 |
| AU2002247696B2 (en) | 2006-10-12 |
| EP1364030A2 (de) | 2003-11-26 |
| DE60209883D1 (de) | 2006-05-11 |
| JP2004518442A (ja) | 2004-06-24 |
| NO331375B1 (no) | 2011-12-12 |
| PT1364030E (pt) | 2006-05-31 |
| DE60209883T2 (de) | 2006-09-07 |
| HK1065818A1 (zh) | 2005-03-04 |
| CY1105696T1 (el) | 2010-12-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60209883D1 (de) | Übersekretierte peptide, deren herstellung, und gleichzeitige verbesserung der sekretierten form eines oder mehrerer anderer polypeptide | |
| CN1483831B (zh) | 获得具有正确键合的胱氨酸键的胰岛素或胰岛素衍生物的方法 | |
| George-Nascimento et al. | Characterization of recombinant human epidermal growth factor produced in yeast | |
| NO965411L (no) | N-terminalt forlengede proteiner uttrykt i gjær | |
| ATE421977T1 (de) | Reinigung von peptiden unter verwendung von metall-ion-affinitätschromatographie | |
| KR920016463A (ko) | 펩티드의 제조방법 | |
| DE10342794A1 (de) | Sekretion von Proteinen aus Hefen | |
| Aitken | Prokaryote-eukaryote relationship and the amino acid sequence of plastocyanin from Anabaena variabilis | |
| ATE342367T1 (de) | Verwendung von fusionsproteinen, deren n- terminaler teil aus einem hirudinderivat besteht, zur herstellung rekombinanter proteine durch sekretion durch hefen | |
| DE3852706D1 (de) | Verfahren zur Herstellung eines physiologisch aktiven Peptids mit einem Cysteinrest. | |
| DE69827262D1 (de) | Penaeidine: antimikrobielle peptide aus krebstieren | |
| ATE408016T1 (de) | Verfahren zur herstellung und sekretion modifizierter peptide | |
| KR900700500A (ko) | 재조합 유전자 기술에 의한 에라스타제 억제 폴리펩티드 제조방법 및 에라스타제 억제 폴리펩티드 | |
| Canova-Davis et al. | Transpeptidation during the analytical proteolysis of proteins | |
| EP0528686B8 (de) | Verfahren zur Herstellung von Peptiden | |
| US5656456A (en) | Chemical method for selective modification of the N- and/or C-terminal amino acid α-carbon reactive group of a recombinant polypeptide or a portion thereof | |
| DE60037508D1 (de) | Verfahren zur herstellung von rekombinantem insulin durch fusionsproteine | |
| JP5909812B2 (ja) | 生物的に生成される環状アフィニティータグ | |
| ES2072422T3 (es) | Procedimiento para la produccion de peptidos amidados en alfa en el terminal c. | |
| ES2316588T3 (es) | Metodo para hacer polipeptidos acilados. | |
| WO2004011599A2 (en) | Polypeptide cleavage process | |
| ATE122398T1 (de) | Signalpeptid und dafür kodierende dns-sequenzen. | |
| HK1061870B (en) | Improved process for obtaining insulin precursors having correctly bonded cystine bridges | |
| JPH1171396A5 (de) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1364030 Country of ref document: EP |